Aethlon Medical develops immunotherapeutic technologies to combat cancer and infectious disease. The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for 1) the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and 2) life-threatening viruses that are not addressed with approved therapies.
Aethlon Medical is currently conducting a safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo®(nivolumab) in Australia and India. The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial in each country is safety. Additionally, Aethlon Medical is conducting a clinical trial for Sars-CoV-2 in India.